http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109553581-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-88 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-88 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 |
| filingDate | 2019-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109553581-B |
| titleOfInvention | Substituted urea compounds, pharmaceutically acceptable salts or solvates thereof, uses thereof, medicaments and pharmaceutical compositions |
| abstract | The present invention provides a substituted urea compound, a pharmaceutically acceptable salt thereof, or a solvate thereof. The invention also provides application of the substituted urea compound, the pharmaceutically acceptable salt or the solvate thereof as an inhibitor of one of MET, VEGFR, PDGFR and RET or application of the substituted urea compound, the pharmaceutically acceptable salt or the solvate thereof in preparation of a multi-target inhibitor of two or more of MET, VEGFR, PDGFR and RET, and application of the substituted urea compound, the pharmaceutically acceptable salt or the solvate thereof in preparation of a drug for regulating kinase activity or treatingUse in a medicament or pharmaceutical composition for the treatment of a kinase-associated disease. The invention also provides a medicament or a pharmaceutical composition for treating the angiogenesis abnormal diseases. The structure of the substituted urea compound is shown as a formula (I), R 1 Selected from methoxy or deuterated methoxy; r 2 Selected from methyl, deuterated methyl, Any one of the structures of (1); r 3 Is selected from any one of F, Cl, Br and I. |
| priorityDate | 2018-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 340.